Post-earnings recap
Reported
Mon, Aug 2, 2021
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The disappointing earnings report, particularly the larger-than-expected loss per share, led to a significant drop in the stock price. Investors reacted negatively, reflecting concerns about the company's financial health and future profitability. Without guidance, uncertainty remains about TG Therapeutics' strategic direction and potential recovery.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | -$0.59 | N/A | -22.15% |
Management expressed concerns about the current financial performance and the path to profitability. They reiterated their commitment to advancing their pipeline despite the losses.
Management highlighted ongoing challenges in achieving profitability.
They emphasized the need for continued investment in research and development.